Astrocytes may drive chronic traumatic encephalopathy, review finds

A Kansas City University scoping review says astrocytes may play a much bigger role in chronic traumatic encephalopathy than previously thought. The findings could shift research toward earlier diagnosis, new biomarkers and therapies for people exposed to repeated head trauma.

Why it matters: - The review suggests chronic traumatic encephalopathy may be driven by more than tau buildup in neurons. - Astrocytic dysfunction may appear early, before widespread neuronal degeneration. - That could change how researchers look for CTE, target treatment and identify people at risk after repetitive head impacts.

What happened: - Kansas City University School of Medicine researchers led by Dr. Kameron Hahn published a scoping review on astrocytes and CTE. - The paper examined 40 studies across postmortem human brain analyses, experimental models, molecular research and biomarker work. - The review appeared in Volume 12 of the Chinese Neurosurgical Journal on May 21, 2026. - The original paper is titled Astrocytic contributions to the pathogenesis of chronic traumatic encephalopathy: a scoping review.

The details: - Astrocytes are star-shaped glial cells that help maintain the blood-brain barrier, regulate neuron-to-neuron communication, support metabolism and clear waste from brain tissue. - The review identified four recurring themes in the literature: interface-specific astrogliosis, disruption of aquaporin-4 waste-clearance pathways, astrocytic degeneration tied to impaired glutamate regulation and chronic neuroinflammation involving astrocytes and microglia. - Several studies found astrocyte activation in brain regions that take the greatest mechanical stress from repetitive head impacts, especially around blood vessels and deep in cortical sulci. - The findings suggest astrocytes may help drive the disease cascade rather than simply responding to existing injury. - The review highlights the glymphatic system, which relies on astrocyte-regulated aquaporin-4 channels to clear metabolic waste and potentially harmful proteins. - Repeated brain injury may disrupt that waste-clearance system and contribute to accumulation of hyperphosphorylated tau, a hallmark of CTE pathology. - Evidence reviewed by the authors also points to sustained inflammation involving astrocytes and microglia after repeated injury. - That inflammatory process may accelerate tissue damage and contribute to cognitive, behavioral and neurological decline. - Glial fibrillary acidic protein, or GFAP, emerged as a candidate biomarker for astrocytic injury. - No biomarker currently provides a definitive diagnosis of CTE in living individuals. - Astrocyte-derived markers may eventually become part of multimodal diagnostic approaches for people at risk before irreversible damage occurs.

Between the lines: - The review challenges the long-held view of CTE as mainly a neuron-centered tau disease. - The authors frame CTE as a disorder involving dysfunction across neuroglial and neurovascular systems. - That broader view could open new therapeutic targets beyond neurons alone. - The paper also signals growing interest in biomarkers that could detect brain injury earlier, before symptoms become permanent.

What's next: - Future research is likely to test whether astrocytic changes can improve early detection of CTE. - Scientists may also look for treatments that target astrocyte, microglial and glymphatic dysfunction after repetitive head trauma. - Dr. Hahn said the findings may help guide earlier diagnostic tools and more effective interventions for people affected by repetitive head injuries.

The bottom line: - Astrocytes may be central, not secondary, in CTE.